{
  "main_header": {
    "sid": 799751,
    "name": "Pharmaids Pharma",
    "stock_name": "Pharmaids Pharma",
    "full_name": "Pharmaids Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/pharmaids-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "50.99",
    "chg": -0.54,
    "chgp": "-1.05%",
    "dir": -1,
    "prev_price": "51.53",
    "mcapval": "179.83 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524572,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE117D01018",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.89 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/pharmaids-pharma-799751-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Pharmaids Pharma Sees Revision in Market Evaluation Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pharmaids-pharma-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-outlook-3746457",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/PharmaidsPharma_mojoScore_3746457.png",
        "date": "2025-12-04 11:08:19",
        "description": "Pharmaids Pharma has undergone a revision in its market evaluation, reflecting a more cautious analytical perspective driven by recent financial and technical developments. The shift highlights concerns over the company’s operational performance and market positioning within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Pharmaids Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pharmaids-pharma-fallingrising-3745001",
        "imagepath": "",
        "date": "2025-12-04 00:51:21",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Pharmaids Pharmaceuticals Ltd's stock price has demonstrated resilience in the short term, gaining 4.54% over the past week compared to the Sensex's decline of 0.59%. This recent surge contrasts with the stock's longer-term performance, where it has declined by 29.77% year-to-date and 23.85% over the last year, while the Sensex has posted gains of 8.92% and 5.27% respectively over the same periods. Notably, the stock has outperformed its sector by 3.83% on the day of 03-Dec, signalling renewed investor interest.</p>\n<p>On the day in question, Pharmaids opened with a gap up of 2.54%, indicating strong buying momentum from the outset. The stock reached an intraday high of ₹50.99, marking a 6.94% increase from the previous close, before s..."
      },
      {
        "title": "Why is Pharmaids Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pharmaids-pharma-fallingrising-3708698",
        "imagepath": "",
        "date": "2025-11-17 23:01:35",
        "description": "As of 17-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a price increase, currently at Rs 47.82, which reflects a rise of Rs 3.41 or 7.68%. Today's price summary indicates that the stock opened with a gain of 4.48% and reached an intraday high of Rs 48, marking an 8.08% increase. However, despite this positive movement, the stock has shown a decline of 1.24% over the past week and a significant drop of 32.15% year-to-date. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 66.97% against the 5-day average, which may indicate waning interest despite today's gains.\n\nBroader market context shows that while Pharmaids Pharmaceuticals has outperformed its sector by 7.4% today, it has underperformed the Sensex over the past week and month, which have seen gains of 1.69% and 1.19%, respectively. The stock's long-term performance remains strong, with a 3-ye..."
      },
      {
        "title": "Why is Pharmaids Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pharmaids-pharma-fallingrising-3702580",
        "imagepath": "",
        "date": "2025-11-14 23:01:57",
        "description": "As of 14-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 44.13, which reflects a decrease of Rs 1.68 or 3.67%. The stock has underperformed significantly today, with a performance that is 4.04% lower than its sector. It has also touched an intraday low of Rs 43.9, indicating a drop of 4.17%. The stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), and there has been a notable decrease in investor participation, with delivery volume falling by 29.48% compared to the 5-day average. Furthermore, the stock is close to its 52-week low, being only 4.83% away from Rs 42. The year-to-date return is down by 37.39%, and the one-year return shows a decline of 41.90%, highlighting a significant downturn in performance.\n\nIn the broader market context, the Sensex has shown a positive return of 1.62% over the past week, contrasting s..."
      },
      {
        "title": "How has been the historical performance of Pharmaids Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-pharmaids-pharma-3694747",
        "imagepath": "",
        "date": "2025-11-12 23:53:35",
        "description": "Answer:\nThe historical performance of Pharmaids Pharma shows a gradual increase in net sales, reaching 19.45 Cr in March 2025, up from 15.11 Cr in March 2024 and starting from 0.00 Cr in March 2023. However, the company has consistently reported negative operating profits, with an operating profit of -12.66 Cr in March 2025, slightly worse than -12.33 Cr in March 2024 and -9.88 Cr in March 2023. The total expenditure has risen to 32.21 Cr in March 2025 from 28.32 Cr in March 2024, contributing to a profit before tax of -17.28 Cr in March 2025, compared to -15.62 Cr in March 2024 and -9.91 Cr in March 2023. The profit after tax also reflects this trend, with losses of -13.51 Cr in March 2025, -11.84 Cr in March 2024, and -7.56 Cr in March 2023. The company's total assets increased to 109.35 Cr in March 2025 from 84.67 Cr in March 2024, while total liabilities also rose to 109.35 Cr from 84.67 Cr, indicating ..."
      },
      {
        "title": "Are Pharmaids Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-pharmaids-pharma-latest-results-good-or-bad-3693212",
        "imagepath": "",
        "date": "2025-11-12 19:31:25",
        "description": "Pharmaids Pharmaceuticals has reported its financial results for Q2 FY26, revealing a complex situation characterized by significant revenue growth alongside persistent operational challenges. The company achieved net sales of ₹8.61 crores, marking a year-on-year growth of 64.31% and a quarter-on-quarter increase of 29.28%. This represents the highest quarterly revenue in the company's history. However, despite this top-line expansion, Pharmaids continues to face substantial net losses, reporting a consolidated net loss of ₹2.48 crores for the quarter, which reflects a 28.50% deterioration year-on-year.\n\nThe operating margin remains deeply negative at -61.67%, indicating ongoing struggles with cost management and profitability. The company's PAT margin also stands at a negative -29.38%, underscoring the challenges in converting revenue into profit. Notably, employee costs have risen significantly, consuming..."
      },
      {
        "title": "Pharmaids Pharmaceuticals Q2 FY26: Mounting Losses and Deteriorating Margins Signal Deepening Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/pharmaids-pharmaceuticals-q2-fy26-mounting-losses-and-deteriorating-margins-signal-deepening-crisis-3692709",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PharmaidsPharma_quaterlyResult_3692709.png",
        "date": "2025-11-12 09:46:45",
        "description": "Pharmaids Pharmaceuticals Ltd., a Hyderabad-based micro-cap pharmaceutical company, reported a consolidated net loss of ₹2.48 crores in Q2 FY26, marking a deterioration of 28.50% year-on-year from the ₹1.93 crore loss in Q2 FY25. The company's stock has plummeted 44.43% over the past year, currently trading at ₹46.29 with a market capitalisation of ₹162.00 crores, reflecting investor exodus from this loss-making enterprise."
      },
      {
        "title": "When is the next results date for Pharmaids Pharma?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-pharmaids-pharma-3681220",
        "imagepath": "",
        "date": "2025-11-07 23:20:02",
        "description": "The next results date for Pharmaids Pharma is scheduled for 11 November 2025...."
      },
      {
        "title": "Why is Pharmaids Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pharmaids-pharma-fallingrising-3677067",
        "imagepath": "",
        "date": "2025-11-06 22:50:47",
        "description": "As of 06-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 46.64, which represents a decrease of Rs 1.57 or 3.26%. The stock has been underperforming, having fallen consecutively for the last two days, resulting in a total drop of 6.38% during this period. Today's trading saw the stock reach an intraday high of Rs 51.91 but ultimately closed at its low. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a rise in delivery volume by 6.9% against the 5-day average, the overall performance today was still below the sector average by 2.49%.\n\nIn the broader market context, Pharmaids Pharmaceuticals has significantly underperformed compared to the benchmark Sensex over various time frames. For instance, in the past week, the stock has declined by 6.92%, while the Sensex has onl..."
      }
    ],
    "total": 89,
    "sid": "799751",
    "stock_news_url": "https://www.marketsmojo.com/news/pharmaids-pharmaceuticals-799751"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "30-Nov-2025",
      "details": "Newspaper publication of Postal Ballot Notice",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
      "datetime": "29-Nov-2025",
      "details": "Intimation of Postal Ballot notice",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "28-Nov-2025",
      "details": "Intimation of appointment of Dr.Yogananda Moolemath (DIN: 02870387) as an Independent Director subject to approval of shareholder appointment of Mr.P N Vinay (DIN: 00047985) as chairman of the Board and appointment of Dr.S.N.Vinaya Babu (DIN: 01373832) as Vice-chairman of the Board.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Pharmaids Pharma Sees Revision in Market Evaluation Amidst Challenging Fundamentals

2025-12-04 11:08:19

Pharmaids Pharma has undergone a revision in its market evaluation, reflecting a more cautious analytical perspective driven by recent financial and technical developments. The shift highlights concerns over the company’s operational performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Read More

Why is Pharmaids Pharma falling/rising?

2025-12-04 00:51:21

Recent Price Movement and Market Context

Pharmaids Pharmaceuticals Ltd's stock price has demonstrated resilience in the short term, gaining 4.54% over the past week compared to the Sensex's decline of 0.59%. This recent surge contrasts with the stock's longer-term performance, where it has declined by 29.77% year-to-date and 23.85% over the last year, while the Sensex has posted gains of 8.92% and 5.27% respectively over the same periods. Notably, the stock has outperformed its sector by 3.83% on the day of 03-Dec, signalling renewed investor interest.

On the day in question, Pharmaids opened with a gap up of 2.54%, indicating strong buying momentum from the outset. The stock reached an intraday high of ₹50.99, marking a 6.94% increase from the previous close, before s...

Read More

Why is Pharmaids Pharma falling/rising?

2025-11-17 23:01:35

As of 17-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a price increase, currently at Rs 47.82, which reflects a rise of Rs 3.41 or 7.68%. Today's price summary indicates that the stock opened with a gain of 4.48% and reached an intraday high of Rs 48, marking an 8.08% increase. However, despite this positive movement, the stock has shown a decline of 1.24% over the past week and a significant drop of 32.15% year-to-date. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 66.97% against the 5-day average, which may indicate waning interest despite today's gains. Broader market context shows that while Pharmaids Pharmaceuticals has outperformed its sector by 7.4% today, it has underperformed the Sensex over the past week and month, which have seen gains of 1.69% and 1.19%, respectively. The stock's long-term performance remains strong, with a 3-ye...

Read More

Why is Pharmaids Pharma falling/rising?

2025-11-14 23:01:57

As of 14-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 44.13, which reflects a decrease of Rs 1.68 or 3.67%. The stock has underperformed significantly today, with a performance that is 4.04% lower than its sector. It has also touched an intraday low of Rs 43.9, indicating a drop of 4.17%. The stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), and there has been a notable decrease in investor participation, with delivery volume falling by 29.48% compared to the 5-day average. Furthermore, the stock is close to its 52-week low, being only 4.83% away from Rs 42. The year-to-date return is down by 37.39%, and the one-year return shows a decline of 41.90%, highlighting a significant downturn in performance. In the broader market context, the Sensex has shown a positive return of 1.62% over the past week, contrasting s...

Read More

How has been the historical performance of Pharmaids Pharma?

2025-11-12 23:53:35

Answer: The historical performance of Pharmaids Pharma shows a gradual increase in net sales, reaching 19.45 Cr in March 2025, up from 15.11 Cr in March 2024 and starting from 0.00 Cr in March 2023. However, the company has consistently reported negative operating profits, with an operating profit of -12.66 Cr in March 2025, slightly worse than -12.33 Cr in March 2024 and -9.88 Cr in March 2023. The total expenditure has risen to 32.21 Cr in March 2025 from 28.32 Cr in March 2024, contributing to a profit before tax of -17.28 Cr in March 2025, compared to -15.62 Cr in March 2024 and -9.91 Cr in March 2023. The profit after tax also reflects this trend, with losses of -13.51 Cr in March 2025, -11.84 Cr in March 2024, and -7.56 Cr in March 2023. The company's total assets increased to 109.35 Cr in March 2025 from 84.67 Cr in March 2024, while total liabilities also rose to 109.35 Cr from 84.67 Cr, indicating ...

Read More

Are Pharmaids Pharma latest results good or bad?

2025-11-12 19:31:25

Pharmaids Pharmaceuticals has reported its financial results for Q2 FY26, revealing a complex situation characterized by significant revenue growth alongside persistent operational challenges. The company achieved net sales of ₹8.61 crores, marking a year-on-year growth of 64.31% and a quarter-on-quarter increase of 29.28%. This represents the highest quarterly revenue in the company's history. However, despite this top-line expansion, Pharmaids continues to face substantial net losses, reporting a consolidated net loss of ₹2.48 crores for the quarter, which reflects a 28.50% deterioration year-on-year. The operating margin remains deeply negative at -61.67%, indicating ongoing struggles with cost management and profitability. The company's PAT margin also stands at a negative -29.38%, underscoring the challenges in converting revenue into profit. Notably, employee costs have risen significantly, consuming...

Read More

Pharmaids Pharmaceuticals Q2 FY26: Mounting Losses and Deteriorating Margins Signal Deepening Crisis

2025-11-12 09:46:45

Pharmaids Pharmaceuticals Ltd., a Hyderabad-based micro-cap pharmaceutical company, reported a consolidated net loss of ₹2.48 crores in Q2 FY26, marking a deterioration of 28.50% year-on-year from the ₹1.93 crore loss in Q2 FY25. The company's stock has plummeted 44.43% over the past year, currently trading at ₹46.29 with a market capitalisation of ₹162.00 crores, reflecting investor exodus from this loss-making enterprise.

Read More

When is the next results date for Pharmaids Pharma?

2025-11-07 23:20:02

The next results date for Pharmaids Pharma is scheduled for 11 November 2025....

Read More

Why is Pharmaids Pharma falling/rising?

2025-11-06 22:50:47

As of 06-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 46.64, which represents a decrease of Rs 1.57 or 3.26%. The stock has been underperforming, having fallen consecutively for the last two days, resulting in a total drop of 6.38% during this period. Today's trading saw the stock reach an intraday high of Rs 51.91 but ultimately closed at its low. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a rise in delivery volume by 6.9% against the 5-day average, the overall performance today was still below the sector average by 2.49%. In the broader market context, Pharmaids Pharmaceuticals has significantly underperformed compared to the benchmark Sensex over various time frames. For instance, in the past week, the stock has declined by 6.92%, while the Sensex has onl...

Read More

View All News